Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men’s Health Company

Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company (“Metuchen”), focused on identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health conditions, today announced that the two companies have entered into a definitive merger agreement under which Metuchen and Neurotrope, Inc. (“Neurotrope”) will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. (“Petros”). Petros is expected to become a Nasdaq traded company focused solely on men’s health conditions. Petros’ cornerstone product would be Metuchen’s Stendra┬« (avanafil) for erectile dysfunction (“ED”).

Read the full article: Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men’s Health Company //

Source: https://www.prnewswire.com/news-releases/neurotrope-and-metuchen-pharmaceuticals-announce-merger-agreement-to-form-petros-pharmaceuticals-a-mens-health-company-301060769.html

Scroll to Top